FDA Approves Trial of Collidem for Treating Advanced Colorectal Cancer

IDM (Immuno-Designed Molecules) reported it has received approval from the U.S. Food and Drug Administration (FDA) to launch a Phase I/II clinical trial of its therapeutic vaccine Collidem™ for the treatment of advanced colorectal cancer.

Collidem is comprised of the patient's own dendritic cells associated with a combination of selected peptides licensed from Epimmune, Inc.

Thirty seven adult patients with advanced colorectal cancer that has not responded to standard treatments will be enrolled in the one-year Phase I/II clinical trial, which will provide the first opportunity to evaluate tolerance, immunologic activity, and clinical response to the vaccine.

Two research centers will participate in the trial: the Universityd of California, San Francisco Medical Center and the City of Hope National Medical Center in Los Angeles.

Other sources: IDM